Technologies

SetLance exploits a tetra-branched (left) or di-branched (right) peptide format for the construction of long-lived molecules to be developed as new drugs.

fig-dimero-generico-3

 

 

 

 

 

 

 

 

SetLance develops new lead peptide sequences, which are optimized, characterized in vitro, and eventually developed in the preclinical, and early clinical phases.

References

  • Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high density multiple antigenic peptide system. Proc.Natl.Acad.Sci.USA. 1988, 85, 5409–5413
  • Bracci L, Falciani C, Lelli B, Lozzi L, Runci Y, Pini A, De Montis MG, Tagliamonte A, Neri P. Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem. 2003, 278:46590-5.
  • Falciani C, Lozzi L, Pini A, Bracci L. Bioactive peptides from libraries. Chem Biol. 2005, 12:417-26.
  • Falciani C, Lozzi L, Pini A, et al. Molecular basis of resistance to enzyme proteolysis. Chem Biol Drug Des. 2007, 69:216–21.
  • Pini A, Falciani C, Bracci L. Branched peptides as therapeutics. Curr Protein Pept Sci. 2008, 9:468-77